PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Cost reduction while Biotechnology median is -15.55%. Seth Klarman would investigate competitive advantage potential.
100.00%
Gross profit growth exceeding 1.5x Biotechnology median of 21.12%. Joel Greenblatt would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D change of 10.75% versus flat Biotechnology spending. Walter Schloss would verify adequacy.
-21.32%
G&A reduction while Biotechnology median is 0.00%. Seth Klarman would investigate efficiency gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth exceeding 1.5x Biotechnology median of 0.03%. Jim Chanos would check for waste.
1.47%
Total costs growth while Biotechnology reduces costs. Peter Lynch would examine differences.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A change of 6.88% versus flat Biotechnology D&A. Walter Schloss would verify adequacy.
-1.39%
EBITDA decline while Biotechnology median is 2.40%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Operating income decline while Biotechnology median is 2.46%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Other expenses reduction while Biotechnology median is -9.26%. Seth Klarman would investigate advantages.
-1.89%
Pre-tax income decline while Biotechnology median is 0.10%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Net income decline while Biotechnology median is -0.01%. Seth Klarman would investigate causes.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth 50-75% of Biotechnology median of 4.00%. Guy Spier would scrutinize operations.
2.63%
Diluted EPS growth 50-75% of Biotechnology median of 4.00%. Guy Spier would scrutinize operations.
3.22%
Share count reduction below 50% of Biotechnology median of 0.46%. Jim Chanos would check for issues.
3.22%
Diluted share reduction below 50% of Biotechnology median of 0.57%. Jim Chanos would check for issues.